Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PSMA

PSMA

Brief Information

Name:Prostate-Specific Membrane Antigen
Target Synonym:EC:3.4.17.21,GIG27,Glutamate carboxypeptidase II,NAALADase I,FOLH,Cell growth-inhibiting gene 27 protein,PSM,N-acetylated-alpha-linked acidic dipeptidase I,GCPII,Folylpoly-gamma-glutamate carboxypeptidase,Folate hydrolase 1,FOLH1,Pteroylpoly-Gamma-Glutamate Carboxypeptidase,Membrane Glutamate Carboxypeptidase,Glutamate Carboxypeptidase 2,Glutamate Carboxylase II,NAALAD1,FGCP,PSMA,MGCP,Folate Hydrolase (Prostate-Specific Membrane Antigen) 1,N-Acetylated Alpha-Linked Acidic Dipeptidase 1,Prostate
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:43
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

PSA-HP2Q3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-PSMA CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human PSMA, His Tag (Cat. No. PSA-HP2Q3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

PSA-H5264-Cell-based assay
 PSMA FACS

2e5 of PSMA-CAR-293 cells transfected with anti-PSMA-scFv were stained with 100 μL of 1 μg/mL of Biotinylated Human PSMA, His,Avitag (Cat. No. PSA-H5264) and negative control protein respectively, washed and then followed by PE anti-human IgG Fc antibody and analyzed with FACS (Routiney tested).

PSA-H5264-ELISA
 PSMA ELISA

Immobilized Human PSMA, Fc Tag (Cat. No. PSA-H5264) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

PSA-R5245-MALS-HPLC
Rat PSMA, His Tag (Cat. No. ) MALS images

The purity of Rat PSMA, His Tag (Cat. No. PSA-R5245) is more than 90% and the molecular weight of this protein is around 170-208 kDa verified by SEC-MALS.

Bioactivity

Measured by its ability to hydrolyze the substrate N-acetyl-L-Asp-L-Glu into N-acetyl-L-Asp and L-Glu. The L-Glu product is measured by fluorescence after its derivatization by ortho-phthaldialdehyde. The specific activity is >300 pmol/min/μg, as measured under the described conditions (QC tested).

Customer Reviews

Synonym Name

FOLH1,PSMA,GIG27,FOLH,NAALAD1,PSM,NAALADase I,GCPII,FGCP

Background

The biotinylated PSMA protein was conjugated to streptavidin magnetic beads. This pre-coupled magnetic bead product can capture the anti-PSMA antibody from various assay systems. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This PSMA coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready-to-use product could greatly save your time and hassle.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Capromab pendetide lndium-CYT-356; Indium-111-CYT-356; CYT-356; 111In CYT-356 Approved Eusa Pharma ProstaScint United States Prostatic Neoplasms Cytogen Corp 1996-10-28 Prostatic Neoplasms Details
Lutetium (177Lu) vipivotide tetraxetan PSMA-617-[177Lu]; Lutetium-177-PSMA-617; 177-Lu-PSMA-617; AAA-617; Lu-177- RLT Approved Radiomedix Inc PLUVICTO United States Prostatic Neoplasms, Castration-Resistant Advanced Accelerator Applications Usa Inc 2022-03-23 Carcinoma, Verrucous; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis Details
Piflufolastat F 18 Approved Johns Hopkins University Pylarify United States Prostatic Neoplasms Progenics Pharmaceuticals Inc 2021-05-26 Carcinoma, Renal Cell; Prostatic Neoplasms; Breast Neoplasms; Genital Neoplasms, Female; Neoplasm Metastasis; Adenocarcinoma Details
Ga-68 PSMA-11 Ga-68-PSMA-11; Ga-68-PSMA; 68Ga-HBED-CC-PSMA11 Approved Radiomedix Inc Gallium Ga 68 Psma-11, Illuccix, ILLUCCIX, Locametz United States Prostatic Neoplasms Telix Pharmaceuticals Ltd, University Of California, San Francisco Foundation 2020-12-01 Solid tumours; Neoplasm Recurrence, Local; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CART-PSMA-TGFbRDN (University of Pennsylvania) Phase 1 Clinical University Of Pennsylvania Prostatic Neoplasms Details
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center Phase 1 Clinical Roger Williams Medical Center Prostatic Neoplasms Details
68Ga-PSMA-R2 (Advanced Accelerator Applications SA) Clinical Advanced Accelerator Applications Sa Prostatic Neoplasms Details
TLX-592 TLX-592 Phase 2 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
CONV-01-alpha + PSMA I&T Phase 2 Clinical Convergent Therapeutics Inc Prostatic Neoplasms Details
ARX-517 ARX-517 Phase 1 Clinical Ambrx Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
123-I-MIP-1095 123-I-MIP-1095 Details
123I-MIP-1072 123-I-MIP-1072 Details
[131I]MIP-1095 1095; [131I]MIP-1095; [131I]MIP-1466 Progenics Pharmaceuticals Inc Details
JNJ-63898081 JNJ-8081; JNJ-63898081 Janssen Global Services Llc Details
177Lu-PSMA-R2 177Lu-PSMA-R2; 177Lu-PSMA-SR6; AAA-602 Phase 2 Clinical Advanced Accelerator Applications Sa Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
Pelgifatamab corixetan BAY-2315497 Phase 1 Clinical Bayer AG Prostatic Neoplasms Details
LAVA-1207 LAVA-1207 Phase 2 Clinical Vu University Medical Center Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1; (177Lu) rhPSMA-10.1 Phase 2 Clinical Blue Earth Therapeutics Ltd Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Urogenital Neoplasms; Prostatic Diseases Details
Anti-PSMA CAR T-cell therapy (TNK Therapeutics) Phase 1 Clinical Sorrento Therapeutics Inc Neoplasms Details
INO-5401 INO-5401 Phase 2 Clinical Inovio Pharmaceuticals Inc Glioblastoma; Carcinoma, Transitional Cell Details
CBP-1018 CBP-1018 Phase 1 Clinical Coherent Biopharma Suzhou Co Ltd Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Lung Neoplasms Details
68Ga-PSMA-IRDye TLX591-Sx Phase 2 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
CCW-702 CCW-702 Phase 1 Clinical The Scripps Research Institute Inc, Abbvie Inc Prostatic Neoplasms Details
177Lu-EB-vipivotide tetraxetan 177-Lu-EB-PSMA-617 Phase 1 Clinical National Institute For Biomedical Imaging And Bioengineering (Nibib), Peking Union Medical College Hospital Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Adenoid Cystic; Prostatic Neoplasms Details
PSMA-CART cell therapy (Shanghai Bioray Laboratory) Phase 1 Clinical Bioray Laboraytories Inc Prostatic Neoplasms Details
P28z-CAR P28z-CAR Phase 1 Clinical Memorial Sloan Kettering Cancer Center, United States Department Of Defense Prostatic Neoplasms Details
67Cu-SAR-bisPSMA (Clarity Pharmaceuticals) Phase 2 Clinical Clarity Pharmaceuticals Ltd Prostatic Neoplasms, Castration-Resistant Details
64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) Phase 2 Clinical Clarity Pharmaceuticals Ltd Prostatic Neoplasms, Castration-Resistant Details
GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR GD2/PSMA Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Solid tumours Details
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell Details
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR PSMA/CD70 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
Gallium-68 PSMA-617 225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DKFZ-PSMA -617; 68Ga-DOTA-PSMA-DKFZ -617; Gallium-68-PSMA-617; PSMA-617-[68Ga] Phase 3 Clinical Peking Union Medical College Hospital Prostatic Neoplasms Details
89Zr-DFO-huJ591 Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 Phase 2 Clinical Memorial Sloan Kettering Cancer Center Prostatic Neoplasms Details
225 Actinium PSMA 617 (Novartis) 225 Actinium PSMA-617; 225Ac-PSMA 617; AAA 817; 225Ac-PSMA-617 Phase 1 Clinical Novartis Pharma Ag, Endocyte Inc, Advanced Accelerator Applications Sa Prostatic Neoplasms, Castration-Resistant Details
CC-1 CC-1 Phase 2 Clinical The University Of Tubingen, German Cancer Research Center (Dkfz) Prostatic Neoplasms, Castration-Resistant; Carcinoma, Squamous Cell Details
Lu-177-DGUL PSMA-D GUL; Lu-177-DGUL; 177Lu-DOTA-GUL Phase 2 Clinical Cellbion Co Ltd Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Neoplasms Details
JANX-007 JANX-007; PSMA-TRACTr Phase 1 Clinical Janux Therapeutics Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
HPN-424 HPN-424 Phase 2 Clinical Harpoon Therapeutics Prostatic Neoplasms Details
Lutetium-177-PSMA-I&T Phase 2 Clinical Radboud University Nijmegen Prostatic Neoplasms Details
Ga-68-NGUL Phase 2 Clinical Cellbion Co Ltd Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
[177Lu]Ludotadipep Phase 2 Clinical Futurechem Prostatic Neoplasms, Castration-Resistant Details
TNB-585 AMG-340; TNB-585 Phase 1 Clinical Teneobio Inc, Amgen Inc Prostatic Neoplasms, Castration-Resistant Details
REGN-4336 REGN-4336 Phase 2 Clinical Regeneron Pharmaceuticals Inc Prostatic Neoplasms, Castration-Resistant Details
REGN-5678 REGN-5678 Phase 2 Clinical Regeneron Pharmaceuticals Inc Prostatic Neoplasms, Castration-Resistant Details
18F-PSMA-1007 18F-PSMA-1007 Phase 3 Clinical Deutsches Krebsforschungszentrum Prostatic Neoplasms Details
Acapatamab AMG-160 Phase 2 Clinical Amgen Inc Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung Details
JNJ-80038114 JNJ-80038114 Phase 1 Clinical Janssen Research & Development Llc Prostatic Neoplasms Details
Fluorine-18-CTT-1057 CTT-1057; 18F-CTT1057; CTT-1057-18F; CTT-1057-F-18 Phase 3 Clinical Washington University, Cancer Targeted Technology Llc Recurrence; Carcinoma, Renal Cell; Prostatic Neoplasms Details
[177Lu]-CTT-1403 CTT-1403; [177Lu]CTT1403; 177Lutetium CTT1403; [177Lu]CTT-1403 Phase 1 Clinical Cancer Targeted Technology Llc Prostatic Neoplasms Details
ATL-101 MLN-591RL; ATL-101; huJ-591; MLN-591; J-591; Lu-177-J591; 177Lu-J591; 90Y-J591; muJ-591 Phase 2 Clinical Weill Medical College of Cornell University Ovarian Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung Details
177Lu-DOTA-rosopatamb TLX591; 177Lu-DOTA-TLX591-CHO Phase 3 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
177Lu-HTK03170 177Lu-HTK03170 Phase 2 Clinical British Columbia Cancer Agency Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
68Ga-labeled NY108 68-Ga-labeled NY-108 Phase 1 Clinical Affiliated Hospital Of Jiangnan University Prostatic Neoplasms Details
[Lu177]-PNT-2002 PNT-2002 Phase 3 Clinical Point Biopharma Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
225Ac-J591 225Ac-DOTA-J591; 225Ac-J591; CONV 01-α Phase 2 Clinical Cornell University Prostatic Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message